A high fat diet with a high C18:0/C16:0 ratio induced worse metabolic and transcriptomic profiles in C57BL/6 mice.
Animals
Body Weight
/ drug effects
Diet, High-Fat
/ adverse effects
Fatty Acids
/ pharmacology
Insulin Resistance
Interleukin-6
/ blood
Lipid Metabolism
/ drug effects
Male
Mice
Mice, Inbred C57BL
MicroRNAs
/ metabolism
Palmitic Acid
/ pharmacology
RNA, Long Noncoding
/ metabolism
RNA, Messenger
/ metabolism
Stearic Acids
/ pharmacology
Tumor Necrosis Factor-alpha
/ blood
High fat diet
Long non-coding RNA
Metabolic profile
Palmitic acid
Stearic acid
Transcriptomic profile
mRNA
microRNA
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
21 Jul 2020
21 Jul 2020
Historique:
received:
10
02
2020
accepted:
09
07
2020
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
8
6
2021
Statut:
epublish
Résumé
Differential effects of individual saturated fatty acids (SFAs), particularly stearic acid (C18:0), relative to the shorter-chain SFAs have drawn interest for more accurate nutritional guidelines. However, specific biologic and pathologic functions that can be assigned to particular SFAs are very limited. The present study was designed to compare changes in metabolic and transcriptomic profiles in mice caused by a high C18:0 diet and high palmitic acid (C16:0) diet. Male C57BL/6 mice were assigned to a normal fat diet (NFD), a high fat diet with high C18:0/C16:0 ratio (HSF) or an isocaloric high fat diet with a low C18:0/C16:0 ratio (LSF) for 10 weeks. An oral glucose tolerance test, 72-h energy expenditure measurement and CT scan of body fat were done before sacrifice. Fasting glucose and lipids were determined by an autobiochemical analyzer. Blood insulin, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) levels were measured by enzyme-linked immunosorbent assay methods. Free fatty acids (FFAs) profiles in blood and liver were determined by using gas chromatography-mass spectrometry. Microarray analysis was applied to investigate changes in transcriptomic profiles in the liver. Pathway analysis and gene ontology analysis were applied to describe the roles of differentially expressed mRNAs. Compared with the NFD group, body weight, body fat ratio, fasting blood glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), triglyceride, IL-6, serum and liver FFAs including total FFAs, C16:0 and C18:0 were increased in both high fat diet groups and were much higher in the HSF group than those in the LSF group. Both HSF and LSF mice exhibited distinguishable long non-coding RNA (lncRNA), microRNA and mRNA expression profiles when compared with those of NFD mice. Additionally, more differentially expressed lncRNAs and mRNAs were observed in the HSF group than in the LSF group. Some biological functions and pathways, other than energy metabolism regulation, were identified as differentially expressed mRNAs between the HSF group and the LSF group. The high fat diet with a high C18:0/C16:0 ratio induced more severe glucose and lipid metabolic disorders and inflammation and affected expression of more lncRNAs and mRNAs than an isocaloric low C18:0/C16:0 ratio diet in mice. These results provide new insights into the differences in biological functions and related mechanisms, other than glucose and lipid metabolism, between C16:0 and C18:0.
Sections du résumé
BACKGROUND
BACKGROUND
Differential effects of individual saturated fatty acids (SFAs), particularly stearic acid (C18:0), relative to the shorter-chain SFAs have drawn interest for more accurate nutritional guidelines. However, specific biologic and pathologic functions that can be assigned to particular SFAs are very limited. The present study was designed to compare changes in metabolic and transcriptomic profiles in mice caused by a high C18:0 diet and high palmitic acid (C16:0) diet.
METHODS
METHODS
Male C57BL/6 mice were assigned to a normal fat diet (NFD), a high fat diet with high C18:0/C16:0 ratio (HSF) or an isocaloric high fat diet with a low C18:0/C16:0 ratio (LSF) for 10 weeks. An oral glucose tolerance test, 72-h energy expenditure measurement and CT scan of body fat were done before sacrifice. Fasting glucose and lipids were determined by an autobiochemical analyzer. Blood insulin, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) levels were measured by enzyme-linked immunosorbent assay methods. Free fatty acids (FFAs) profiles in blood and liver were determined by using gas chromatography-mass spectrometry. Microarray analysis was applied to investigate changes in transcriptomic profiles in the liver. Pathway analysis and gene ontology analysis were applied to describe the roles of differentially expressed mRNAs.
RESULTS
RESULTS
Compared with the NFD group, body weight, body fat ratio, fasting blood glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), triglyceride, IL-6, serum and liver FFAs including total FFAs, C16:0 and C18:0 were increased in both high fat diet groups and were much higher in the HSF group than those in the LSF group. Both HSF and LSF mice exhibited distinguishable long non-coding RNA (lncRNA), microRNA and mRNA expression profiles when compared with those of NFD mice. Additionally, more differentially expressed lncRNAs and mRNAs were observed in the HSF group than in the LSF group. Some biological functions and pathways, other than energy metabolism regulation, were identified as differentially expressed mRNAs between the HSF group and the LSF group.
CONCLUSION
CONCLUSIONS
The high fat diet with a high C18:0/C16:0 ratio induced more severe glucose and lipid metabolic disorders and inflammation and affected expression of more lncRNAs and mRNAs than an isocaloric low C18:0/C16:0 ratio diet in mice. These results provide new insights into the differences in biological functions and related mechanisms, other than glucose and lipid metabolism, between C16:0 and C18:0.
Identifiants
pubmed: 32693810
doi: 10.1186/s12944-020-01346-z
pii: 10.1186/s12944-020-01346-z
pmc: PMC7372854
doi:
Substances chimiques
Fatty Acids
0
Interleukin-6
0
MicroRNAs
0
RNA, Long Noncoding
0
RNA, Messenger
0
Stearic Acids
0
Tumor Necrosis Factor-alpha
0
Palmitic Acid
2V16EO95H1
stearic acid
4ELV7Z65AP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
172Subventions
Organisme : National Natural Science Foundation of China
ID : 81202188
Références
Cell Mol Life Sci. 2019 Jul;76(13):2547-2557
pubmed: 30968170
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Jan;1863(1):26-39
pubmed: 28986283
Andrologia. 2019 Jun;51(5):e13259
pubmed: 30873638
Lipids. 2005 Dec;40(12):1187-91
pubmed: 16477801
Int J Mol Sci. 2019 May 28;20(11):
pubmed: 31142011
Eur J Nutr. 2016 Apr;55(3):967-79
pubmed: 25930966
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Oct 15;878(28):2817-25
pubmed: 20846914
Mitochondrion. 2019 May;46:73-90
pubmed: 29551309
Arch Biochem Biophys. 2003 Nov 15;419(2):101-9
pubmed: 14592453
Nutrients. 2016 Mar 02;8(3):128
pubmed: 26950145
Metabolism. 2018 Jun;83:42-49
pubmed: 29410352
Mol Plant. 2017 Apr 3;10(4):619-633
pubmed: 28111288
Am J Clin Nutr. 2019 Aug 1;110(2):305-315
pubmed: 31179489
Proc Nutr Soc. 2019 May;78(2):234-245
pubmed: 30630554
Front Endocrinol (Lausanne). 2019 Aug 21;10:577
pubmed: 31496996
Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198
pubmed: 25818339
Clin Exp Immunol. 2015 Jan;179(1):90-9
pubmed: 25169121
Physiol Behav. 2014 Apr 10;128:70-9
pubmed: 24518863
Nutr Res Rev. 2010 Dec;23(2):270-99
pubmed: 20977819
J Am Diet Assoc. 2011 Jan;111(1):28-39
pubmed: 21185961
Nat Rev Immunol. 2017 Apr;17(4):233-247
pubmed: 28192415
Am J Clin Nutr. 2000 Oct;72(4):905-11
pubmed: 11010930
Nat Med. 2007 Oct;13(10):1193-202
pubmed: 17906635
Clin Exp Allergy. 2020 Feb;50(2):244-255
pubmed: 31837231
Br J Nutr. 1987 May;57(3):383-93
pubmed: 3109464
Cell Metab. 2014 Mar 4;19(3):380-92
pubmed: 24508507
J Med Invest. 2007 Aug;54(3-4):243-7
pubmed: 17878672
Am J Physiol Regul Integr Comp Physiol. 2018 Nov 1;315(5):R934-R944
pubmed: 30088983
Diabetes. 2002 Mar;51(3):624-30
pubmed: 11872659
Ann Nutr Metab. 2009;55(1-3):229-43
pubmed: 19752544
Trends Pharmacol Sci. 2017 Jul;38(7):649-665
pubmed: 28551355
Nutr Metab (Lond). 2010 Mar 27;7:24
pubmed: 20346174
Adv Exp Med Biol. 2015;872:217-33
pubmed: 26215996
Cell Physiol Biochem. 2018;48(3):1317-1331
pubmed: 30048968
Diabet Med. 2007 Sep;24(9):934-45
pubmed: 17725706
Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):752-8
pubmed: 18089958
Lipids. 1997 Feb;32(2):143-9
pubmed: 9075203
Cell Rep. 2016 Jun 28;16(1):201-212
pubmed: 27320917
Diabetologia. 2016 Jun;59(6):1247-57
pubmed: 26969487
Cell Signal. 2016 Jan;28(1):53-9
pubmed: 26475209
Prog Lipid Res. 2020 Jan;77:101020
pubmed: 31870728
Clin Nutr. 2004 Aug;23(4):447-56
pubmed: 15297079
J Biol Chem. 2016 Feb 19;291(8):4069-78
pubmed: 26703471
Adv Exp Med Biol. 2017;960:277-304
pubmed: 28585204